KCT0008772招募中Unknown
An open-label, randomized, multicentre, phase ? trial of Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers
ational Cancer Center0 个研究点目标入组 98 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 98
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •Patients aged at least 19 years old, diagnosed with unresectable pancreaticobiliary cancer, and scheduled to receive chemotherapy using nal-IRI/5-FU/LV combination chemotherapy
排除标准
- •Patients who refuse to sign the consent form
- •Patients who have previously experienced severe neutropenia during chemotherapy
研究者
相似试验
进行中（未招募）
不适用
A study of RO5083945 in combination with chemotherapy versus chemotherapy alone in patients with advanced or recurrent non-small cell lung cancerocally advanced (stage IIIb), metastatic (IV) or recurrent, non-small cell lung cancer who have not received prior chemotherapyMedDRA version: 14.1Level: LLTClassification code 10025077Term: Lung carcinoma stage IVSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10025076Term: Lung carcinoma stage IIISystem Organ Class: 100000004864EUCTR2010-018945-72-DEF.Hoffmann-La Roche160
进行中（未招募）
1 期
A study of RO5083945 in combination with chemotherapy versus chemotherapy alone in patients with advanced or recurrent non-small cell lung cancerocally advanced (stage IIIb), metastatic (IV) or recurrent, non-small cell lung cancer who have not received prior chemotherapyMedDRA version: 14.0 Level: LLT Classification code 10025076 Term: Lung carcinoma stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0 Level: LLT Classification code 10025077 Term: Lung carcinoma stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018945-72-GBF.Hoffmann-La Roche93
进行中（未招募）
1 期
A study of RO5083945 in combination with chemotherapy versus chemotherapy alone in patients with advanced or recurrent non-small cell lung cancerocally advanced (stage IIIb), metastatic (IV) or recurrent, non-small cell lung cancer who have not received prior chemotherapyMedDRA version: 14.1Level: LLTClassification code 10025077Term: Lung carcinoma stage IVSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10025076Term: Lung carcinoma stage IIISystem Organ Class: 100000004864EUCTR2010-018945-72-BEF.Hoffmann-La Roche160
进行中（未招募）
1 期
Phase I/II comparison of efficacy and safety of BIBF 1120 and sorafenib in patients with advanced hepatocellular carcinomaHistologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 7 or less, in 1st line systemic therapy.MedDRA version: 14.0Level: LLTClassification code 10049010Term: Carcinoma hepatocellularSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011925-14-SKBoehringer Ingelheim RCV GmbH & Co KG132
进行中（未招募）
1 期
A multicentre, open label, phase I/randomised phase II study to evaluatesafety, pharmacokinetics and efficacy of BIBF 1120 in comparison withSorafenib for advanced hepatocellular carcinoma patientsHistologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 7 or less, in 1st line systemic therapy.EUCTR2009-011925-14-HUBoehringer Ingelheim RCV GmbH & Co KG132